Galectin reports Q3 net loss of $0.13/sh; cash $11.5M; NAVIGATE data submitted to FDA

GALECTIN THERAPEUTICS INC

2025-Q3 EPS reported -$0.40

Net loss of $8.2M ($0.13/share) vs $11.2M ($0.18/share) in Q3 2024; R&D spend down to $2.6M as NAVIGATE trial ended.
Cash and equivalents $11.5M at Sep 30; plus $10M line of credit from chairman; runway through June 2026.
New 18-month NAVIGATE biomarker data showed belapectin reduced portal hypertension risk categories vs placebo.
FDA data package submitted for belapectin in MASH cirrhosis; agency feedback expected by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.